Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform.

ABSTRACT: Snakebite envenoming is a neglected tropical disease that causes as many as 1.8 million envenomings and 140,000 deaths annually. To address treatment limitations that exist with current antivenoms, the search for small molecule drug-based inhibitors that can be administered as early interventions has recently gained traction. Snake venoms are complex mixtures of proteins, peptides and small molecules and their composition varies substantially between and within snake species. The phospholipases A2 (PLA₂) are one of the main pathogenic toxin classes found in medically important viper and elapid snake venoms, yet varespladib, a drug originally developed for the treatment of acute coronary syndrome, remains the only PLA₂ inhibitor shown to effectively neutralise venom to

SUBMITTER: Albulescu LO 

PROVIDER: S-EPMC10808766 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature